Literature DB >> 16567013

Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.

Christian Hildmann1, Dennis Wegener, Daniel Riester, René Hempel, Andreas Schober, Joachim Merana, Laura Giurato, Salvatore Guccione, Tine Kragh Nielsen, Ralf Ficner, Andreas Schwienhorst.   

Abstract

Histone deacetylases (HDACs) are key enzymes in the transcriptional regulation of gene expression in eukaryotic cells. In recent years HDACs have attracted considerable attention as promising new targets in anticancer therapy. Currently, different histone deacetylase subtypes are divided into four groups denoted as classes 1-4. Here, we compare in more detail representatives of class 1 HDACs and FB188 HDAH as a close bacterial homologue of class 2 HDAC6, in regard of substrate and inhibitor specificity. Structure comparison is used to identify candidate regions responsible for observed specificity differences. Knowledge of these structural elements expedite studies on the biochemical role of different HDAC subtypes as well as the development of highly selective HDAC inhibitors as antitumor agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567013     DOI: 10.1016/j.jbiotec.2006.01.030

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  21 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  On the inhibition of histone deacetylase 8.

Authors:  Guillermina Estiu; Nathan West; Ralph Mazitschek; Edward Greenberg; James E Bradner; Olaf Wiest
Journal:  Bioorg Med Chem       Date:  2010-04-03       Impact factor: 3.641

3.  Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs.

Authors:  Tatiana Akimova; Guanghui Ge; Tatiana Golovina; Tatiana Mikheeva; Liqing Wang; James L Riley; Wayne W Hancock
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 4.  Isoform-selective histone deacetylase inhibitors.

Authors:  Anton V Bieliauskas; Mary Kay H Pflum
Journal:  Chem Soc Rev       Date:  2008-05-08       Impact factor: 54.564

Review 5.  Drug targeting of dysregulated transcription in Huntington's disease.

Authors:  Aleksey G Kazantsev; Steven M Hersch
Journal:  Prog Neurobiol       Date:  2007-02-23       Impact factor: 11.685

6.  Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.

Authors:  Raushan K Singh; Tanmay Mandal; Narayanaganesh Balasubramanian; Gregory Cook; D K Srivastava
Journal:  Anal Biochem       Date:  2010-09-22       Impact factor: 3.365

7.  Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Authors:  Shuai Gao; Jie Zang; Qianwen Gao; Xuewu Liang; Qinge Ding; Xiaoyang Li; Wenfang Xu; C James Chou; Yingjie Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-19       Impact factor: 3.641

8.  Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.

Authors:  Anja Schuetz; Jinrong Min; Abdellah Allali-Hassani; Matthieu Schapira; Michael Shuen; Peter Loppnau; Ralph Mazitschek; Nick P Kwiatkowski; Timothy A Lewis; Rebecca L Maglathin; Thomas H McLean; Alexey Bochkarev; Alexander N Plotnikov; Masoud Vedadi; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

9.  Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors.

Authors:  Daniel P Dowling; Stephanie L Gantt; Samuel G Gattis; Carol A Fierke; David W Christianson
Journal:  Biochemistry       Date:  2008-12-23       Impact factor: 3.162

Review 10.  Recent advances in the search for antiviral agents against human papillomaviruses.

Authors:  Amélie Fradet-Turcotte; Jacques Archambault
Journal:  Antivir Ther       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.